$NTRA

Sheena Jonathan sold $837K of NTRA

Sheena Jonathan sold 3,150 shares of Natera, Inc. (NTRA) at an average of $265.68 ($262.72–$268.39, $0.84M total) across 6 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Jul 16, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

Traders may monitor for patterns in insider activity, but this specific disclosure lacks new fundamentals and is unlikely to drive a durable repricing by itself.

02

Market read

A disclosed insider sale by a director under a 10b5-1 plan, with no accompanying company-specific news.

03

What to watch

The article does not state whether other insiders sold/bought around the same time, nor does it quantify total insider ownership changes beyond the post-transaction share count.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed after-hours on 2026-07-15, covering sales dated 2026-07-13.

Background

The article is an SEC Form 4 insider transaction for Natera, Inc., reported by a director and executed as an open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera director Sheena Jonathan sold about 3,150 shares in an open-market sale totaling $836,898.26 under a 10b5-1 plan.

Expected impact

Likely limited, short-lived impact; any reaction should fade unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the article provides no new guidance, contracts, or regulatory developments.

Market effects

Minimal. No sector-wide read-across is provided beyond a single-company insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, the transaction may reflect scheduled liquidity needs rather than bearish expectations, so any negative tape reaction could be overdone.

Key entities

  • Natera, Inc.

    Company whose director insider sale is disclosed via SEC Form 4.

  • Sheena Jonathan

    Director who sold shares totaling $836,898.26 across six trades on 2026-07-13.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.